Identification of Novel Transcriptome Signature as a Potential Prognostic Biomarker for Anti-Angiogenic Therapy in Glioblastoma Multiforme

Glioblastoma multiforme (GBM) is the most common and devastating type of primary brain tumor, with a median survival time of only 15 months. Having a clinically applicable genetic biomarker would lead to a paradigm shift in precise diagnosis, personalized therapeutic decisions, and prognostic predic...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Shuhua, Tao, Wensi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7957709/
https://www.ncbi.nlm.nih.gov/pubmed/33804433
http://dx.doi.org/10.3390/cancers13051013

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7957709/
https://www.ncbi.nlm.nih.gov/pubmed/33804433
http://dx.doi.org/10.3390/cancers13051013

Ejemplares similares